Tisagenlecleucel - Biologic Drug Details

Summary for tisagenlecleucel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for tisagenlecleucel

Recent Clinical Trials for tisagenlecleucel

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Memorial Sloan Kettering Cancer Center	PHASE3
Princess Maxima Center for Pediatric Oncology	PHASE3
Stanford University	PHASE1

See all tisagenlecleucel clinical trials

Pharmacology for tisagenlecleucel

Mechanism of Action	CD19 Receptor Interactions
Physiological Effect	Increased T Lymphocyte Activation
Established Pharmacologic Class	CD19-directed Chimeric Antigen Receptor Genetically-modified Autologous T Cells
Chemical Structure	CD19-specific Chimeric Antigen Receptor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tisagenlecleucel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tisagenlecleucel Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2035-04-07	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2036-07-21	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2041-09-15	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2042-05-23	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for tisagenlecleucel Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2040-09-16	Patent claims search

International Patents for tisagenlecleucel

Country	Patent Number	Estimated Expiration
Chile	2022002522
Cyprus	2019007
Singapore	11201606909R
Australia	2025200842

Supplementary Protection Certificates for tisagenlecleucel

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
PA2019503	Lithuania		PRODUCT NAME: TISAGENLEKLEUCELAS; REGISTRATION NO/DATE: EU/1/18/1297 20180823
C201930005	Spain		PRODUCT NAME: TISAGENLECLEUCEL; NATIONAL AUTHORISATION NUMBER: EU/1/18/1297; DATE OF AUTHORISATION: 20180823; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1297; DATE OF FIRST AUTHORISATION IN EEA: 20180823
C20190004 00283	Estonia		PRODUCT NAME: TISAGEENLEKLEUTSEEL;REG NO/DATE: EU/1/18/1297 27.08.2018
C02649086/01	Switzerland		PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66778 18.10.2018

Market Dynamics and Financial Trajectory for Tisagenlecleucel

Last updated: February 12, 2026

Tisagenlecleucel, marketed as Kymriah by Novartis, is a CAR-T cell therapy approved for certain hematologic malignancies. Its market prospects are shaped by regulatory approvals, competitive landscape, manufacturing complexities, reimbursement patterns, and evolving clinical data.

Therapeutic Indications and Market Penetration

Tisagenlecleucel targets B-cell precursor acute lymphoblastic leukemia (ALL) in patients up to age 25 and diffuse large B-cell lymphoma (DLBCL) in adults. Launched in 2017, Kymriah captured early market share due to its first-mover advantage but faced competition from rival CAR-T therapies like Gilead's Yescarta (axicabtagene ciloleucel) and Bristol-Myers Squibb's Breyanzi (lisocabtagene maraleucel).

In 2022, Kymriah's global sales totaled approximately $584 million, reflecting steady growth driven by expanded indications and then recent approvals for additional indications. The US accounted for about 75% of revenue, with Europe and emerging markets making up the remainder.

Regulatory and Clinical Expansion

Novartis seeks label expansions for tisagenlecleucel, particularly for earlier lines of therapy and additional lymphoma subtypes. Emergency use authorizations and pipeline progress bolster potential growth. The company's development of next-generation CAR-Ts aims to improve efficacy and reduce adverse events.

In 2021, the FDA approved Kymriah for adult r/r DLBCL, broadening its scope. Approval in additional countries depends on local regulatory assessments, affecting faster uptake in key markets.

Manufacturing Challenges and Costs

Manufacturing tisagenlecleucel involves personalized processes requiring patient-specific cell collection, genetic modification, and multicenter logistics. These factors cause high production costs, lead times of 3-4 weeks, and constraints on scaling.

In 2022, Novartis reported manufacturing costs exceeding $200,000 per dose, with a typical list price around $475,000. Reimbursement frameworks vary globally; in the US, CMS and private insurers' coverage influences patient access and sales volume.

Competitive Landscape

Yescarta, Breyanzi, and newer CAR-Ts, including Johnson & Johnson's Carvykti, challenge Kymriah. These therapies differ in manufacturing, side effect profiles, and indications. Market share shifts depend heavily on clinical data, approval of expanded labels, and cost-effectiveness.

Emerging Trends and Market Drivers

1. Pipeline Development: Novartis continues trials for Kymriah in multiple myeloma, multiple solid tumors, and earlier disease stages.
2. Combination Therapies: Trials combining CAR-T with checkpoint inhibitors or other immunotherapies may expand indications.
3. Cost Management: Efforts focus on reducing manufacturing costs, optimizing supply chains, and streamlining administration.

Financial Outlook and Valuation

Novartis projects CAR-T sales to reach over $1 billion by 2025, assuming successful expansion and market penetration. The global CAR-T market is projected to grow at a CAGR of 25% through 2030, driven by approval of novel products and adoption in earlier lines of treatment.

Pricing strategies, reimbursement policies, and advancements in manufacturing will determine profitability margins. Competitor entry and clinical trial outcomes could influence Kymriah's long-term market share.

Summary Table

Aspect	Key Data Points
2022 Global Sales	$584 million
2022 US Share	75%
List Price per Dose	~$475,000
Manufacturing Cost per Dose	Exceeds $200,000
Leading Competitors	Yescarta, Breyanzi, Carvykti
Estimated Market CAGR (2023-2030)	25%

Key Takeaways

Tisagenlecleucel's market trajectory depends on expanding indications, manufacturing improvements, and competitive dynamics. While current revenue levels are moderate, pipeline progress and broader clinical adoption suggest potential for substantial growth. Cost management and reimbursement strategies will influence its long-term commercial success.

FAQs

1. What are the main limitations affecting tisagenlecleucel's market growth? Manufacturing complexity, high costs, and limited reimbursement access restrict broader deployment.

2. How does tisagenlecleucel compare to rivals in efficacy? Clinical trials show comparable remission rates to Yescarta and Breyanzi in approved indications but vary based on patient populations.

3. Are there upcoming approvals that could boost sales? Yes, ongoing trials aim to expand indications in multiple myeloma and solid tumors, which could increase market size.

4. What impact does manufacturing cost have on pricing? High production costs justify the premium price, but payers demand value-based arrangements, influencing net margins.

5. What trends could threaten tisagenlecleucel's market position? Entry of more effective or better-priced competitors, or regulatory hurdles delaying new approvals, could erode market share.

---

Sources:
[1] Novartis Financial Reports, 2022.
[2] FDA Approvals and Label Expansions, 2021-2022.
[3] Industry Analyst Reports, 2022-2023.